NASDAQ:MESO Mesoblast (MESO) Stock Price, News & Analysis → The Military's $700M 'AI Software Bullet' (From Behind the Markets) (Ad) Free MESO Stock Alerts $7.24 -0.04 (-0.55%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$7.22▼$7.4550-Day Range$4.69▼$8.5252-Week Range$1.61▼$10.24Volume65,088 shsAverage Volume1.31 million shsMarket Capitalization$826.66 millionP/E RatioN/ADividend YieldN/APrice Target$13.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Mesoblast alerts: Email Address Mesoblast MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside88.8% Upside$13.67 Price TargetShort InterestHealthy0.44% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.17Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.71) to ($0.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.38 out of 5 starsMedical Sector498th out of 913 stocksBiological Products, Except Diagnostic Industry72nd out of 152 stocks 3.1 Analyst's Opinion Consensus RatingMesoblast has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageMesoblast has only been the subject of 1 research reports in the past 90 days.Read more about Mesoblast's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.44% of the outstanding shares of Mesoblast have been sold short.Short Interest Ratio / Days to CoverMesoblast has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mesoblast has recently decreased by 35.95%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMesoblast does not currently pay a dividend.Dividend GrowthMesoblast does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MESO. Previous Next 3.4 News and Social Media Coverage News SentimentMesoblast has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Mesoblast this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for MESO on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows8 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mesoblast insiders have not sold or bought any company stock.Percentage Held by Insiders18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.43% of the stock of Mesoblast is held by institutions.Read more about Mesoblast's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mesoblast are expected to grow in the coming year, from ($0.71) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mesoblast is -6.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mesoblast is -6.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMesoblast has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Mesoblast's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About Mesoblast Stock (NASDAQ:MESO)Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Read More MESO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MESO Stock News HeadlinesJune 14 at 7:45 AM | americanbankingnews.comMesoblast (NASDAQ:MESO) Trading Down 2.1%June 9, 2024 | americanbankingnews.comMesoblast (NASDAQ:MESO) Shares Gap Up to $6.82June 7, 2024 | americanbankingnews.comMesoblast (NASDAQ:MESO) Stock Price Down 3.3%June 2, 2024 | globenewswire.comMesoblast Corporate Presentation at Investor ConferenceMay 28, 2024 | msn.comASX 200 ‘drifts off’ after ‘weaker-than-expected’ retail sales numbersMay 27, 2024 | msn.comOvercoming long-term unemployment by getting physically and mentally fit to join the workforceMay 16, 2024 | msn.com‘Best day for the market this year’: ASX 200 rises 1.65 per centMay 3, 2024 | msn.comIf you invested $8,000 in Mesoblast shares at the beginning of 2024, guess how much you'd have now!May 2, 2024 | msn.comASX 200 closes down 1.23 per cent on WednesdayMay 1, 2024 | msn.comAustralia stocks lower at close of trade; S&P/ASX 200 down 1.23%April 30, 2024 | msn.comYen falls after suspected intervention on Monday, eyes on FedApril 30, 2024 | msn.comWhy is the Mesoblast share price taking a dive on Tuesday?April 29, 2024 | globenewswire.comAppendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024April 29, 2024 | msn.comSoft landing remains within reach as consumer spending spree set for breather: UBSApril 29, 2024 | msn.comStablecoin Tether is losing market share - reportApril 29, 2024 | msn.comUS Dollar Uptrend on Thin Ice as Fed Takes Center Stage This WeekApril 16, 2024 | msn.comInsiders are buying Mesoblast and these ASX sharesApril 10, 2024 | seekingalpha.comMesoblast Limited: Back From The DeadApril 5, 2024 | msn.comWhy is everyone talking about Mesoblast shares?April 4, 2024 | finance.yahoo.comSpinal Fusion Pipeline Report 2024, Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key CompaniesApril 3, 2024 | msn.comFed members back cutting rates this year, but need confidence inflation slowingApril 3, 2024 | investorplace.comFeeling Bold? 3 Aggressive Plays to 10X Your Returns by 2025April 3, 2024 | au.investing.comTop ASX Stocks for this MonthApril 2, 2024 | fool.com.auMesoblast share price dumps 10% as excitement simmers on FDA submissionApril 2, 2024 | au.investing.comWhat is next for Tesla stock after soft Q1 sales reportSee More Headlines Receive MESO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/30/2023Today6/17/2024Next Earnings (Estimated)6/20/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:MESO Previous SymbolOTCMKTS:MBLTY CUSIPN/A CIK1345099 Webwww.mesoblast.com Phone(139) 639-6036Fax61-3-9639-6030Employees83Year FoundedN/APrice Target and Rating Average Stock Price Target$13.67 High Stock Price Target$34.00 Low Stock Price Target$3.00 Potential Upside/Downside+85.4%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.21 Current Ratio2.71 Quick RatioN/A Sales & Book Value Annual Sales$7.50 million Price / Sales112.20 Cash FlowN/A Price / Cash FlowN/A Book Value$6.16 per share Price / Book1.20Miscellaneous Outstanding Shares114,180,000Free Float92,713,000Market Cap$841.51 million OptionableOptionable Beta3.46 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Silviu Itescu FACP (Age 67)FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Comp: $738.74kDr. Eric A. Rose M.D. (Age 73)Chief Medical Officer & Executive Director Comp: $625.46kMr. Andrew Chaponnel B.Com.Interim Chief Finance OfficerMr. Peter T. Howard B.Sc. (Age 56)L.L.B., LLB (Hons), General Counsel & Corporate Executive Mr. Roger D. Brown BAHead of Spinal Orthopedic DisordersMr. Michael Schuster BSc (Age 47)M.B.A., MS, Head of Pharma Partnering Ms. Geraldine Storton B.Sc.M.B.A., MMS, Head of Regulatory Affairs & Quality ManagementMr. Justin Horst B.S.Head of ManufacturingMs. Niva Sivakumar B.Com.L.L.B., Joint Company SecretaryMr. Paul Hughes BPHARMJoint Company SecretaryMore ExecutivesKey CompetitorsDenali TherapeuticsNASDAQ:DNLITwist BioscienceNASDAQ:TWSTArcellxNASDAQ:ACLXSpringWorks TherapeuticsNASDAQ:SWTXApogee TherapeuticsNASDAQ:APGEView All CompetitorsInstitutional OwnershipChase Investment Counsel CorpBought 59,600 shares on 5/2/2024Ownership: 0.052%Penbrook Management LLCSold 150,175 shares on 4/18/2024Ownership: 0.110%Chapin Davis Inc.Sold 7,000 shares on 4/18/2024Ownership: 0.009%View All Institutional Transactions MESO Stock Analysis - Frequently Asked Questions Should I buy or sell Mesoblast stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares. View MESO analyst ratings or view top-rated stocks. What is Mesoblast's stock price target for 2024? 6 analysts have issued 12 month price targets for Mesoblast's stock. Their MESO share price targets range from $3.00 to $34.00. On average, they anticipate the company's stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 88.8% from the stock's current price. View analysts price targets for MESO or view top-rated stocks among Wall Street analysts. How have MESO shares performed in 2024? Mesoblast's stock was trading at $2.20 at the beginning of 2024. Since then, MESO shares have increased by 229.1% and is now trading at $7.24. View the best growth stocks for 2024 here. Are investors shorting Mesoblast? Mesoblast saw a drop in short interest in the month of May. As of May 31st, there was short interest totaling 500,800 shares, a drop of 36.0% from the May 15th total of 781,900 shares. Based on an average daily volume of 2,230,000 shares, the days-to-cover ratio is presently 0.2 days. View Mesoblast's Short Interest. When is Mesoblast's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 20th 2024. View our MESO earnings forecast. How were Mesoblast's earnings last quarter? Mesoblast Limited (NASDAQ:MESO) announced its quarterly earnings data on Wednesday, August, 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.06. The business earned $2.14 million during the quarter, compared to analysts' expectations of $2 million. When did Mesoblast's stock split? Mesoblast shares reverse split before market open on Friday, January 5th 2024. The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split. What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV). When did Mesoblast IPO? Mesoblast (MESO) raised $69 million in an initial public offering (IPO) on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers. Who are Mesoblast's major shareholders? Mesoblast's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Penbrook Management LLC (0.11%), Chase Investment Counsel Corp (0.05%) and Chapin Davis Inc. (0.01%). How do I buy shares of Mesoblast? Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MESO) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.